Revenue is increasing over prior year period but expenses in the last quarter were up mainly due to the costs of getting the FDA trial up and running .
Sales in upcoming quarters should be growing as their product becomes available in more parts of the world and recell sales appear to be gaining traction.
I believe they are still getting $1.5m in military grant money and with the existing cash and fortrend capital money they should have more than enough to get FDA approval and become cashflow positive.
Ann: Appendix 4C - quarterly , page-3
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.47 |
Change
-0.060(2.37%) |
Mkt cap ! $168.2M | |||
| Open | High | Low | Value | Volume |
| $2.49 | $2.51 | $2.45 | $478.8K | 192.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 999 | $2.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.51 | 348 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| AVH (ASX) Chart |